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to MK.
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1058 Correction
Correction to: Leukemia 32, 252–262 (2018);
https://doi.org/10.1038/leu.2017.329;
published online February 2018
Following the publication of this article the authors noted
that the MRD data under the Table 1 column “Remark” of
Aspire should go to that of Pollux. The authors wish to
apologize for any inconvenience caused. The corrected
table is attached to this correction.
Table. Major clinical trials of next generation PIs (car-
ﬁlzomib, Ixazomib), next generation IMiDs (pomalido-
mide) and monoclonal antibody.
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Study Phase
of study
Novel agent RCT RR/ ≥ CR/ ≥VGPR
in intervention arm
Median PFS
(months) HR
Median OS
(months)
Median number
of prior lines
ASCT Refractory to
last regimen
Bort- & Len-
Refractory
Remark Year of
publication
SIRIUS 2 daratumumab No 29.2/2.8/12.2% 3.7 m 17.5 m 64%
at 12 m
5 80% 97% 95% Refractory MM 2016 [21]
GEN501 2 daratumumab No 36/5/10% 5.6 m 77% at 12 m
(16 mg/kg)
4 76% 80% 64% Refractory MM 2016 [22]
MM-003 3 pomalidomide POM-dex
vs HD-Dex
31/1/5% 3.8 m vs 1.9 m
HR: 0.48
11.9 vs 7.8 m
HR: 0.74
95% ≥ 3 70% 82% 75/74% Refractory MM 2013 [17]
CASTOR 3 daratumumab DVd vs Vd 83/19/59% NR vs 7.2 m
HR: 0.39
NR in both
arms
2 62% 30% Nil PI-refractory
excluded
2016 [18]
POLLUX 3 daratumumab DRd vs Rd 93/43.1/75.8% NR vs 18.4 m
HR: 0.37
NR in both
arms
1 63% 28/26.9% Nil Len- refractory
excluded
MRD-ve: 22.4%
vs 4.6%
2016 [23]
Eloquent-2 3 elotuzumab Elo-Rd vs
Rd
79/7/33% 19.4 m vs
14.9 m
HR: 0.70
43.7 m vs
39.6 m
HR: 0.77
2 55% 35% Nil 21% bort-
refractory
2015 [20,
45]
ASPIRE 3 carﬁlzomib KRd vs Rd 87/17.7/70% 26.3 m vs
17.6 m
HR: 0.69
NR in both
HR: 0.79
2 NR ?Nil Nil 2015 [15]
TOURMALINE-
MM1
3 ixazomib IRd vs Rd 78/12/36% 20.6 m vs
14.7 m
HR: 0.74
NR in both
arms
90% had ≤ 2
lines
57% 11% Nil Bort- or Len-
refractory
excluded
2016 [16]
Endeavor 3 carﬁlzomib Kd vs Vd 77/11/42% 18.7 m vs 9.4
m
HR: 0.53
47.6 m vs 40
m
HR: 0.79
2 NR Nil Nil Bort-refractory
excluded
2016
[19,26]
POM pomalidomide, HD high-dose, MM multiple myeloma, NR not reached, HR hazard ratio, Bort bortezomib, Len lenalidomide, DRd
daratumumab/lenalidomide/dexamethasone, KRd carﬁlzomib/lenalidomide/dexamethasone, IRd ixazomib/lenalidomide/dexamethasone, Kd
carﬁlzomib/dexamethasone, Vd bortezomib/dexamethasone, MRD-ve minimal residual disease negativity
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